Akebia Therapeutics Inc
SWB:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
SWB:AX9
|
US |
|
V
|
Valtecne SpA
MIL:VLT
|
IT |
|
N
|
National Grid PLC
SWB:NNGF
|
UK |
|
Magazine Luiza SA
BOVESPA:MGLU3
|
BR |
|
Phunware Inc
F:2RJA
|
US |
|
Natwest Group PLC
XETRA:RYSD
|
UK |
|
F
|
Forte Biosciences Inc
F:37TA
|
US |
|
Posco Holdings Inc
NYSE:PKX
|
KR |
|
Klepierre SA
PAR:LI
|
FR |
|
D
|
DENTSPLY SIRONA Inc
SWB:DY2
|
US |
Wall St Price Targets
AX9 Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AX9 is 3.7 EUR with a low forecast of 2.62 EUR and a high forecast of 5.45 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AX9's stock price target?
Price Target
3.7
EUR
According to Wall Street analysts, the average 1-year price target for AX9 is 3.7 EUR with a low forecast of 2.62 EUR and a high forecast of 5.45 EUR.
What is the Revenue forecast for Akebia Therapeutics Inc?
Projected CAGR
-4%
The compound annual growth rate for Revenue over the next 3 years is -4%.
What is the Gross Profit forecast for Akebia Therapeutics Inc?
Projected CAGR
-1%
The compound annual growth rate for Gross Profit over the next 3 years is -1%.
